Daniel Bottomly
Overview
Explore the profile of Daniel Bottomly including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
2197
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Allen B, Bottomly D, Kohnke T, Wang A, Lin H, Johnson K, et al.
Blood
. 2025 Feb;
PMID: 40009487
MDM2 inhibitors are promising therapeutics for acute myeloid leukemia (AML) with wild-type TP53. Through an integrated analysis of functional genomic data from primary patient samples, we found that an MDM2...
2.
Stiff A, Fornerod M, Kain B, Nicolet D, Kelly B, Miller K, et al.
Nat Genet
. 2024 Oct;
56(11):2434-2446.
PMID: 39367245
Genomic profiles and prognostic biomarkers in patients with acute myeloid leukemia (AML) from ancestry-diverse populations are underexplored. We analyzed the exomes and transcriptomes of 100 patients with AML with genomically...
3.
Allen B, Savoy L, Ryabinin P, Bottomly D, Chen R, Goff B, et al.
Br J Haematol
. 2024 Jun;
205(1):207-219.
PMID: 38867543
Upregulation of the Wilms' tumour 1 (WT1) gene is common in acute myeloid leukaemia (AML) and is associated with poor prognosis. WT1 generates 12 primary transcripts through different translation initiation...
4.
Bottomly D, McWeeney S
J Immunother Cancer
. 2024 Mar;
12(3).
PMID: 38531545
Immuno-oncology involves the study of approaches which harness the patient's immune system to fight malignancies. Immuno-oncology, as with every other biomedical and clinical research field as well as clinical operations,...
5.
Lin H, Mohammadhosseini M, McClatchy J, Villamor-Paya M, Jeng S, Bottomly D, et al.
Blood
. 2024 Mar;
143(26):2749-2762.
PMID: 38498025
Identifying and targeting microenvironment-driven pathways that are active across acute myeloid leukemia (AML) genetic subtypes should allow the development of more broadly effective therapies. The proinflammatory cytokine interleukin-1β (IL-1β) is...
6.
Modak R, de Oliveira Rebola K, McClatchy J, Mohammadhosseini M, Damnernsawad A, Kurtz S, et al.
Clin Cancer Res
. 2024 Mar;
30(10):2245-2259.
PMID: 38451486
Purpose: Emerging evidence underscores the critical role of extrinsic factors within the microenvironment in protecting leukemia cells from therapeutic interventions, driving disease progression, and promoting drug resistance in acute myeloid...
7.
Eide C, Kurtz S, Kaempf A, Long N, Joshi S, Nechiporuk T, et al.
Blood Cancer Discov
. 2023 Sep;
4(6):452-467.
PMID: 37698624
Significance: By mapping drug sensitivity data to clinical features and tumor cell state, we identify novel venetoclax combinations targeting patient subtypes who lack sensitivity to Ven + azacytidine. This provides...
8.
Romine K, Bottomly D, Yashar W, Long N, Viehdorfer M, McWeeney S, et al.
Front Oncol
. 2023 Jun;
13:1192829.
PMID: 37361575
Introduction: The implementation of small-molecule and immunotherapies in acute myeloid leukemia (AML) has been challenging due to genetic and epigenetic variability amongst patients. There are many potential mechanisms by which...
9.
Yashar W, Curtiss B, Coleman D, VanCampen J, Kong G, Macaraeg J, et al.
Mol Cancer Res
. 2023 Mar;
21(7):631-647.
PMID: 36976323
Implications: This work establishes the synergistic efficacy of combined FLT3 and LSD1 inhibition in FLT3-ITD AML by disrupting STAT5 and GFI1 binding at the MYC blood-specific superenhancer complex.
10.
Lachowiez C, Long N, Saultz J, Gandhi A, Newell L, Hayes-Lattin B, et al.
Blood Adv
. 2022 Nov;
7(9):1899-1909.
PMID: 36441905
Risk stratification in acute myeloid leukemia (AML) remains principle in survival prognostication and treatment selection. The 2022 European LeukemiaNet (ELN) recommendations were recently published, with notable updates to risk group...